All Stories

  1. New GRADE Evidence-to-Decision Framework for Pairwise and Multiple Comparisons (GRADE Guidance 45)
  2. The Hidden Penalty for UK Clinical Academics: An Overlooked Inequity in Consultant Pay Progression
  3. COPD and kidney disease: not so far apart?
  4. Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  5. Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial
  6. Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  7. The silent exclusion: rethinking eligibility and generalizability in clinical trials
  8. Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments
  9. Reduced treatment response to inhaled corticosteroids in current smokers with COPD, regardless of blood eosinophil count: insights from the FLAME trial
  10. Beyond survival: improving lung cancer rehabilitation through standardised outcomes
  11. Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019
  12. Decoding community-acquired pneumonia: a systematic review and analysis of diagnostic criteria and definitions used in clinical trials
  13. Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  14. Global, regional, and national burden of asthma and atopic dermatitis, 1990–2021, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
  15. Predictors of treatment REsponse to inhaled corticosteroids (ICS) in Chronic Obstructive pulmonary disease: randomised controlled trials individual participant Data re-Evaluation–protocol of the ICS-RECODE individual participant data meta-analysis
  16. Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  17. ERS Congress 2024: highlights from the Airway Diseases Assembly
  18. Prevalence of Respiratory Viruses in Stable and Acute Asthma: A Systematic Review and Meta-Analysis
  19. Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma
  20. Rethinking Blood Eosinophils for Assessing Inhaled Corticosteroids Response in COPD
  21. Steroids in severe community-acquired pneumonia
  22. GRADE guidance 39: using GRADE-ADOLOPMENT to adopt, adapt or create contextualized recommendations from source guidelines and evidence syntheses
  23. Effect of low climate impact vs. high climate impact inhalers for patients with asthma and COPD-a nationwide cohort analysis
  24. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050
  25. Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study
  26. European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
  27. AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries
  28. Unravelling the complexity of ventilator-associated pneumonia: a systematic methodological literature review of diagnostic criteria and definitions used in clinical research
  29. The state of health in the European Union (EU-27) in 2019: a systematic analysis for the Global Burden of Disease study 2019
  30. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  31. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a syst...
  32. Burden of disease scenarios for 204 countries
  33. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  34. Current options in the management of tree nut allergy: A systematic review and narrative synthesis
  35. Recommendations for asthma monitoring in children: A PeARL document endorsed by APAPARI, EAACI, INTERASMA, REG, and WAO
  36. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
  37. Immunomodulatory drugs in sepsis: a systematic review and meta‐analysis
  38. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
  39. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth
  40. Reply to “The use of basophil activation tests (BATs) in the diagnosis of penicillin allergy”
  41. Performance Characteristics of Basophil Activation Tests for Diagnosing Penicillin Allergy: A Meta-Analysis
  42. Prognostic factors for mortality, ICU, MIS-C and hospital admission due to SARS-CoV-2 in paediatric patients: A systematic review and meta-analysis
  43. Inhaledversussystemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis
  44. The Fagerström Test for Nicotine Dependence, as a prognostic factor, in current smokers with and without COPD: A cross-sectional study in northern Greece
  45. Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis
  46. Clinical trials of pneumonia management assess heterogeneous outcomes and measurement instruments
  47. ERS International Congress 2023: highlights from the Airway Diseases Assembly
  48. Prevalence and clinical implications of respiratory viruses in asthma during stable disease state and acute attacks: Protocol for a meta-analysis
  49. Promising treatment biomarkers in asthma
  50. Rethinking Blood Eosinophils for Assessing ICS Response in COPD: A Post-Hoc Analysis from FLAME
  51. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
  52. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  53. Impact of self-reported environmental mould exposure on COPD outcomes
  54. Population pharmacokinetics critically ill beta lactam (ClinicalTrials.gov).
  55. Population pharmacokinetics critically ill beta lactam (Cochrane, CENTRAL).
  56. Population pharmacokinetics critically ill beta lactam (Embase, Ovid).
  57. Population pharmacokinetics critically ill beta lactam (MEDLINE (R) All, Ovid).
  58. Population pharmacokinetics critically ill beta lactam (Web of Science).
  59. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  60. Combined Pulmonary Fibrosis and Emphysema: Comparative Evidence on a Complex Condition
  61. Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022
  62. Current and Optimal Practices in Childhood Asthma Monitoring Among Multiple International Stakeholders
  63. ERS International Congress 2022: highlights from the Airway Diseases Assembly
  64. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
  65. Core outcome sets, developed collaboratively with patients, can improve the relevance and comparability of clinical trials
  66. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID
  67. Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease and Risk of Acquiring Streptococcus pneumoniae Infection. A Multiregional Epidemiological Study
  68. Impact of triple therapy on mortality in COPD
  69. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis
  70. The clinical spectrum of aspergillosis in chronic obstructive pulmonary disease
  71. Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study
  72. How to peer review: practical advice for early career researchers
  73. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe
  74. Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 2019
  75. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis
  76. GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions
  77. West Nile Disease Symptoms and Comorbidities: A Systematic Review and Analysis of Cases
  78. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  79. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
  80. Biomarkers of Clot Activation and Degradation and Risk of Future Major Cardiovascular Events in Acute Exacerbation of COPD: A Cohort Sub-Study in a Randomized Trial Population
  81. Peripheral neuropathy: A neglected cause of disability in COPD – A narrative review
  82. Presence of antiphospholipid antibodies is associated with increased implantation failure following in vitro fertilization technique and embryo transfer: A systematic review and meta-analysis
  83. Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID
  84. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
  85. Transmission of SARS-CoV-2 in educational settings in 2020: a review
  86. Prognostic factors for mortality, ICU and hospital admission due to SARS-CoV-2: A systematic review and meta-analysis of cohort studies in Europe
  87. Inspiring stories: the impact that being part of ERS activities can have on a professional career
  88. Burden of non-communicable diseases among adolescents aged 10–24 years in the EU, 1990–2019: a systematic analysis of the Global Burden of Diseases Study 2019
  89. Outcomes assessed in therapeutic randomized controlled trials in hospitalized patients with COVID-19: is the meta Core Outcome Set (meta-COS) adopted?
  90. Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms
  91. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  92. Intermittent prophylactic antibiotics for bronchiectasis
  93. Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study
  94. Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation
  95. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  96. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
  97. Chronic obstructive pulmonary disease and COVID-19: interrelationships
  98. The role of educational settings in the transmission chain of SARS-CoV-2 in 2020: a systematic review
  99. ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
  100. Automated lung sound analysis using the LungPass platform: a sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19
  101. ERS/EAACI statement on adherence to international adult asthma guidelines
  102. Stigma: an unmet public health priority in COPD
  103. Automated lung sound analysis using the LungPass platform: A sensitive and specific tool for identifying lower respiratory tract involvement in COVID-19
  104. Management of asthma in childhood: study protocol of a systematic evidence update by the Paediatric Asthma in Real Life (PeARL) Think Tank
  105. Corticosteroid Resistance in Smokers—A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial
  106. ERS clinical practice guidelines on treatment of sarcoidosis
  107. Screening, Diagnostic and Prognostic Tests for COVID-19: A Comprehensive Review
  108. The association between beta-blocker therapy and daytime sleepiness in obstructive sleep apnoea
  109. Multidimensional indices in the assessment of chronic obstructive pulmonary disease
  110. Alterations in T and B cell function persist in convalescent COVID-19 patients
  111. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials
  112. Triglyceride-Glucose Index in Non-Diabetic, Non-Obese Patients with Obstructive Sleep Apnoea
  113. Childhood asthma outcomes during the COVID‐19 pandemic: Findings from the PeARL multi‐national cohort
  114. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey
  115. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey
  116. P190 Systematic survey of reported outcomes in ventilator associated pneumonia randomised controlled trials
  117. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis
  118. GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making
  119. Developing trustworthy recommendations as part of an urgent response (1–2 weeks): a GRADE concept paper
  120. Polymorphisms of the Glucocorticoid Receptor Gene and Adrenal Suppression in Patients with Chronic Obstructive Pulmonary Disease Treated with Glucocorticoids for Acute Exacerbations
  121. Outcomes Evaluated in Controlled Clinical Trials on the Management of COVID-19: A Methodological Systematic Review
  122. Current developments and future directions in COPD
  123. COVID-19 and COPD: a narrative review of the basic science and clinical outcomes
  124. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort
  125. Outcomes evaluated in controlled clinical trials on the management of COVID-19: A methodological systematic review
  126. Recovery of monocyte exhaustion is associated with resolution of lung injury in COVID-19 convalescence
  127. Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial
  128. Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19
  129. Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden
  130. Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease
  131. Severity-stratified and longitudinal analysis of VWF/ADAMTS13 imbalance, altered fibrin crosslinking and inhibition of fibrinolysis as contributors to COVID-19 coagulopathy
  132. Comparison of the Level of Awareness about the Transmission of Echinococcosis and Toxocariasis between Pet Owners and Non-Pet Owners in Greece
  133. Problems arising from the conduct of multiple trials evaluating the same interventions for COVID-19
  134. The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision
  135. Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol
  136. Longitudinal immune profiling reveals distinct features of COVID-19 pathogenesis
  137. Research Priorities in Pediatric Asthma: Results of a Global Survey of Multiple Stakeholder Groups by the Pediatric Asthma in Real Life (PeARL) Think Tank
  138. Prevalence and clinical implications of respiratory viruses in stable chronic obstructive pulmonary disease (COPD) and exacerbations: a systematic review and meta-analysis protocol
  139. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits
  140. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD
  141. The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma
  142. ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly
  143. Corrigendum to: Transfusion-Transmitted Malaria: A Systematic Review and Meta-Analysis
  144. Long-Lasting Alterations in T and B Cell Function in Convalescent COVID-19 Patients
  145. A systematic evaluation of the diagnostic criteria for COPD and exacerbations used in randomised controlled trials on the management of COPD exacerbations
  146. Laboratory Cross-Contamination of Mycobacterium tuberculosis: A Systematic Review and Meta-analysis
  147. Transfusion-Transmitted Malaria: A Systematic Review and Meta-analysis
  148. How do clinical trials on COPD exacerbations evaluate the effect treatments have on patients?
  149. Was the implementation strategy of the ProACT trial adequately proactive?
  150. Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration
  151. Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services
  152. Research highlights from the 2018 European Respiratory Society International Congress: airway disease
  153. Intermittent prophylactic antibiotics for bronchiectasis
  154. What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs [Erratum]
  155. Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta-analysis
  156. Biomarkers to guide antibiotic therapy for COPD exacerbations
  157. Capsule Commentary on Ashburner et al., Electronic Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation: a Randomized Controlled Trial
  158. What is the impact of GOLD 2017 recommendations in primary care? – a descriptive study of patient classifications, treatment burden and costs
  159. EARLY versus MILD Chronic Obstructive Pulmonary Disease (COPD)
  160. Continuous versus intermittent antibiotics for bronchiectasis
  161. COPD and Stroke
  162. The emerging Chinese COPD epidemic
  163. Capsule Commentary on Bremmer et. al., Impact of Procalcitonin Guidance on Management of Adults Hospitalized with Chronic Obstructive Pulmonary Disease Exacerbations
  164. Research highlights from the 2017 ERS International Congress: airway diseases in focus
  165. Early Career Members at the ERS International Congress 2017: highlights from the Assemblies
  166. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
  167. Airways diseases: insights from the European Respiratory Society Annual Congress 2017
  168. ERS Early Career Members meet EAACI Junior Members: the launch of a strong, fruitful collaboration
  169. Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis
  170. GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence
  171. Interventions to improve inhaler technique and adherence to inhaled corticosteroids in children with asthma
  172. Opportunities for early career members
  173. Relationship of Allergy with Asthma: There Are More Than the Allergy “Eggs” in the Asthma “Basket”
  174. Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis
  175. Interventions to improve inhaler technique for people with asthma
  176. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis
  177. Early Career Members at the ERS International Congress London 2016
  178. How to keep good clinical records
  179. Prevalence and burden of comorbidities in COPD
  180. Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score
  181. Serum procalcitonin can guide antibiotic administration for respiratory tract infections in primary care
  182. Obstructive Sleep Apnea and Hypertension: A Bidirectional Causal Relation
  183. Overlap Syndrome of Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnoea
  184. The risk of tachyarrhythmias in patients with moderate-to-severe chronic kidney disease receiving tiotropium bromide
  185. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations
  186. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: Are they equivalent?
  187. COPD Phenotypes and Biomarkers: Introducing Personalised Medicine
  188. Management of Stable COPD: An Update
  189. Editorial from Guest Editor (Thematic Issue: Current Approach to COPD Management: Setting a Model in Medical Therapeutics)
  190. Tiotropium HandiHaler Improves the Survival of Patients with COPD: A Systematic Review and Meta-Analysis
  191. Drugs that Act on the Respiratory Tract
  192. Expression of Bmi1, FoxF1, Nanog, and γ-Catenin in Relation to Hedgehog Signaling Pathway in Human Non-small-Cell Lung Cancer
  193. Tiotropium Inhaler Devices: Seeking Convenience When Mortality Is at Stake?
  194. Impact of long‐term treatment with low‐dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: Aggravating or beneficial?
  195. Chronic bronchitis: an objective diagnosis of exclusion